Systemic, local, and sclerotherapy drugs: What do we know about drug prescribing in vascular anomalies?
Pediatr Blood Cancer
; 68(12): e29364, 2021 12.
Article
in En
| MEDLINE
| ID: mdl-34596969
ABSTRACT
Off-label drug prescribing, frequent in the treatment of vascular anomalies (VA), relies on the quality of the literature reporting drug efficacy and safety. Our objective is to review the level of evidence (LOE) surrounding drug use in VA, which is more prevalent in pediatric care. A list of drugs used in VA was created with a literature review in July 2020. For each drug listed, the article displaying the highest LOE was determined and then compared between efficacy/safety data, routes of administration, pharmacological categories and a subset of VA. The influence of research quality on study results was also explored. The median LOE for the 74 drugs identified poor methodological quality, with a predominance of retrospective studies or case reports. Drug safety is currently inadequately reported. This is alarming as many treatments display significant safety concerns. Also, current literature displays major publication bias that probably leads to overestimation of drug efficacy in VA.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Sclerotherapy
/
Vascular Malformations
Type of study:
Observational_studies
Limits:
Child
/
Humans
Language:
En
Journal:
Pediatr Blood Cancer
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Year:
2021
Document type:
Article
Affiliation country:
Canadá